Journal article
Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma
Abstract
BackgroundIn patients with metastatic melanoma and KIT amplifications and/or mutations, therapy with imatinib mesylate may prolong survival. 18F-labeled 2-fluoro-2-deoxy-D-glucose (18F-FDG) PET/CT may be used to assess metabolic response. We investigated associations of metabolic response, mutational status, progression-free survival and overall survival in this population.MethodsBaseline and 4-week follow-up 18F-FDG-PET/CT were evaluated in 17 …
Authors
Zukotynski K; Yap JT; Giobbie-Hurder A; Weber J; Gonzalez R; Gajewski TF; O’Day S; Kim K; Hodi FS; Van den Abbeele AD
Journal
Cancer Imaging, Vol. 14, No. 1,
Publisher
Springer Nature
Publication Date
December 2014
DOI
10.1186/s40644-014-0030-0
ISSN
1740-5025